Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Well-Differentiated Neuroendocrine Carcinoma
High Grade Neuroendocrine Carcinoma, Any Site

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab
DRUG: Hyperpolarized 13C-Pyruvate

Sponsor

University of California, San Francisco

Collaborators

[object Object]